Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Solid Tumor × avelumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 10 Carcinoma, Merkel Cell 7 Urinary Bladder Neoplasms 6 Pancreatic Neoplasms 5 Neoplasm Metastasis 5 Neoplasms 4 Triple Negative Breast Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Prostatic Neoplasms 3 Ovarian Neoplasms 3 Leukemia, Myeloid, Acute 3 Colorectal Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Stomach Neoplasms 2 Sarcoma 2 Melanoma 2 Head and Neck Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Ovarian Epithelial 2 Carcinoma 2 Uterine Cervical Neoplasms 1 Ureteral Neoplasms 1 Solid Tumor 1 Recurrence 1 Ovarian Diseases 1 Non-Muscle Invasive Bladder Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm, Residual 1 Mesothelioma, Malignant 1

Interventions

toripalimab 5 Nivolumab 4 Injections 4 pembrolizumab 3 tislelizumab 2 spartalizumab 2 Paclitaxel 2 Ipilimumab 2 zimberelimab 1 ulocuplumab 1 sotorasib 1 sintilimab 1 osimertinib 1 donafenib 1 binimetinib 1 avelumab 1 atezolizumab 1 WW Domain-Containing Oxidoreductase 1 Immunotherapy, Adoptive 1 Gemcitabine 1 Cisplatin 1 Cetuximab 1 Carboplatin 1 Bevacizumab 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03707808 2025-01-20

myDAvIpNi

Universitair Ziekenhuis Brussel

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡